


AZ'6421

Cat. No.:	HY-135312
CAS No.:	2361115-35-5
Molecular Formula:	C ₅₂ H ₆₅ F ₃ N ₆ O ₇ S
Molecular Weight:	975.17
Target:	Estrogen Receptor/ERR; PROTACs
Pathway:	Others; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AZ'6421 acts as Proteolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer ^[1] .
IC₅₀ & Target	IC ₅₀ : 0.6 nM (ER binding); 0.4 nM (ER degradation) ^[1]
In Vitro	AZ'6421 (example 72) exhibits anti-tumour activity via the ability to degrade the estrogen receptor in a number of different breast cancer cell-lines (MCF-7, CAMA-I, and BT474) ^[1] . AZ'6421 (0.3 μM) has ER binding and ER degradation with IC ₅₀ values of 0.6 nM and 0.4 nM, respectively in MCF-7 cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Bin Yang, et al. Compounds and their use in treating cancer. Patent WO2019123367A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA